Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florbetapir F 18 - Avid Radiopharmaceuticals

Next Previous
Drug Profile

Florbetapir F 18 - Avid Radiopharmaceuticals

Alternative Names: 18F-AV-45; Amyloid imaging agent; Amyvid; AV-45; Florbetapir (18F); Florpiramine F 18

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer Avid Radiopharmaceuticals; Chang Gung Memorial Hospital
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase II Cognition disorders
  • No development reported Parkinson's disease

Most Recent Events

  • 25 Jun 2025 US FDA approves label updation for florbetapir F 18 injection for intravenous use
  • 29 Nov 2022 Phase II development in Cognition disorders (Diagnosis, In adults, In the elderly) is ongoing in Taiwan (IV) (NCT04588649)
  • 16 May 2022 Avid Pharmaceuticals terminated a phase II trial in Alzhiemers disease in Netherlands (EudraCT2012-001599-12)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top